SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
43,200
+550 (1.29%)
Mar 27, 2026, 3:30 PM KST

SK bioscience Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
105,553312,702127,026225,28798,028
Short-Term Investments
380,848233,542275,3005,300-0
Trading Asset Securities
419,900611,864871,8161,250,2181,547,635
Cash & Short-Term Investments
906,3011,158,1081,274,1411,480,8061,645,663
Cash Growth
-21.74%-9.11%-13.96%-10.02%-
Accounts Receivable
122,00894,46212,92839,58538,006
Other Receivables
10,93593,9349,41450,07610,129
Receivables
132,943188,39622,34289,66148,135
Inventory
189,203211,12680,649187,406135,046
Prepaid Expenses
5,7985,7481,6131,6491,407
Other Current Assets
11,88013,2954,22424,1737,554
Total Current Assets
1,246,1251,576,6731,382,9691,783,6941,837,804
Property, Plant & Equipment
1,130,387982,607315,923293,057220,983
Long-Term Investments
234,81122,35742,7291,50021,610
Goodwill
55,25357,436---
Other Intangible Assets
71,83256,08414,1786,2993,973
Long-Term Deferred Tax Assets
124,701108,13559,21921,37010,242
Long-Term Deferred Charges
66,87611,0278,28111,88213,088
Other Long-Term Assets
25,75829,27729,14024,1292,422
Total Assets
2,955,7442,843,5961,852,4392,141,9312,110,123
Accounts Payable
35,28717,8183,37011,05363,812
Accrued Expenses
52,63954,29819,71630,24226,322
Short-Term Debt
---45,55011,671
Current Portion of Long-Term Debt
---38,00847,978
Current Portion of Leases
3,7536,9578,13712,2352,309
Current Income Taxes Payable
1,3806,994-20,216101,486
Other Current Liabilities
233,179224,523104,397222,733206,374
Total Current Liabilities
326,238310,589135,620380,037459,952
Long-Term Debt
464,738383,331--35,503
Long-Term Leases
1,4972,52612,43617,5438,775
Pension & Post-Retirement Benefits
----4,246
Long-Term Deferred Tax Liabilities
64,03671,960---
Other Long-Term Liabilities
61,78052,737527.842,649335.24
Total Liabilities
918,289821,144148,584400,229508,811
Common Stock
39,21739,17438,41438,39238,250
Additional Paid-In Capital
1,236,2721,235,3761,160,4561,160,0081,157,064
Retained Earnings
445,262499,757549,421533,378405,305
Comprehensive Income & Other
68,04928,258-44,4359,924692.92
Total Common Equity
1,788,8001,802,5651,703,8551,741,7021,601,312
Minority Interest
248,654219,887---
Shareholders' Equity
2,037,4542,022,4521,703,8551,741,7021,601,312
Total Liabilities & Equity
2,955,7442,843,5961,852,4392,141,9312,110,123
Total Debt
469,988392,81420,574113,336106,236
Net Cash (Debt)
436,313765,2941,253,5681,367,4691,539,428
Net Cash Growth
-42.99%-38.95%-8.33%-11.17%-
Net Cash Per Share
5569.369913.9516277.2017754.3920850.38
Filing Date Shares Outstanding
78.4378.3576.8376.7876.5
Total Common Shares Outstanding
78.4378.3576.8376.7876.5
Working Capital
919,8871,266,0831,247,3501,403,6571,377,852
Book Value Per Share
22806.2323007.3722177.6022683.1220932.18
Tangible Book Value
1,661,7151,689,0451,689,6781,735,4031,597,339
Tangible Book Value Per Share
21185.9721558.4321993.0622601.0920880.24
Land
91,37771,30745,28045,2709,949
Buildings
426,843425,887124,315127,741119,990
Machinery
167,795174,92255,87953,14151,037
Construction In Progress
372,934231,27465,63833,15325,884
Source: S&P Global Market Intelligence. Standard template. Financial Sources.